Adalimumab for the Management of Post-operative Crohn's Disease (CD)
- Sponsor
- Tel-Aviv Sourasky Medical Center
- Study ID
- NCT01629628
- Phase
- PHASE3
- Status
- Unknown
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Adalimumab — DRUGSubcutaneous adalimumab injections, loading dose of 160 mg and 80 mg on 0 and 2 weeks and maintenance of 40 mg every other week for the duration of the study.
- 6 Mercaptopurine — DRUG6MP will be administered orally starting at a dose of 6MP of 50mg/day with escalating doses every 1-2 weeks as tolerated, to a target dose of 1-1.5 mg/kg. \--------------------------------------------------------------------------------
Study Details
This study will be a prospective, open label, randomized, comparative study. Comparing the efficacy of adalimumab with immunomodulator therapy (i.e. 6-mercaptopurine, 6-MP), in maintaining remission of post-operative CD patients, with a high risk of disease recurrence. Patient assessment for efficacy will be conducted through interval endoscopic surveillance at 24 and 52 weeks. Patients in the adalimumab arm, showing endoscopic remission at 52 weeks of therapy, will be re-randomized to either maintain adalimumab therapy for an additional 52 weeks or conclude therapy. A third endoscopic assessment for these patients will be conducted at 104 weeks. The investigators expect a substantial increase in both endoscopic, as well as clinical remission rate in patients on adalimumab therapy.
Key Dates
- Start date
- Jul 31, 2012
- Status verified
- Jun 2012
- Primary completion
- Jul 31, 2016
- Completion
- Jul 31, 2016
Study Design
- Enrollment
- 100 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- PREVENTION
Arms
- Experimental: Adalimumab
- Active Comparator: 6-mercaptopurine
Primary Outcome Measure
The proportion of patients with endoscopic recurrence at 12 months, as evaluated by the Rutgeerts endoscopic scoring system. [ Time Frame: 52 weeks ]
Central Contacts
- Erez F Scapa, M.D.972-52-4266345
- Sara Pel, MPH972-3-6973011
Related Studies
- Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy ProjectRecruiting · University of California, San Diego · La Jolla, California
- Autologous Stem Cell Transplant for Crohn's DiseasePHASE2 · Recruiting · Aaron Etra · New York, New York
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVOPHASE1 · Recruiting · National Cancer Institute (NCI) · Birmingham, Alabama
- Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF TherapyPHASE1/PHASE2 · Recruiting · Children's Hospital Medical Center, Cincinnati · Hartford, Connecticut